Atlas Trials

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Clinical trial NCT06589440 · RECRUITING

Trial details

NCT number
NCT06589440
Sponsor
Stingray Therapeutics
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Start date
2024-11-20
Primary completion
2027-07-31
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.